Delcath Systems, HEPZATO KIT

Tá Melphalan ceadaithe ag FDA mar chóireáil ae-threoraithe le haghaidh melanoma uveal

Nov 2023: The Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) as a liver-directed treatment for adult patients with uveal melanoma who have unresectable h..

tSín, Trialacha cliniciúla, carcinoma heipiteoceallach, JW Teiripeach, Shanghai

Fógraíonn JW Therapeutics Tionscnamh Staidéar Cliniciúil ar JWATM214 in Othair a bhfuil Ard-charcanóma Hepatocellular acu

SHANGHAI, CHINA, February 28, 2023 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the init..

durvalumab, carcinoma heipiteoceallach, tremelimumab

Tá Tremelimumab ceadaithe ag FDA i gcomhcheangal le durvalumab le haghaidh carcanóma hepatocellular do-dochreidte

November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..

Atezolizumab, Bevacizumab, nivolumab, Regorafenib, Spreagadh, Tecentriq

Drugaí ceadaithe le haghaidh ailse ae a chóireáil

Nollaig 2021: Tá na drugaí seo a leanas ceadaithe amhail an dáta chun ailse ae a chóireáil:. Seiceáil an t-eolas ordaithe le do thoil roimh an druga a ghlacadh. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-SM..

Trasphlandú ae, Liver transplant in Apollo Chennai

Máinliacht ailse ae agus trasphlandú leis an Dr. Selvakumar

July 14, 2021: Check out interview of Dr. Selvakumar Naganathan - Clinical Lead - Liver transplantation and HPB surgery, Apollo Hospitals, Chennai. Check out the video and also excerpts of the interview. https://www.youtube.com..

Atezolizumab, Bevacizumab, Drugaí is déanaí

Atezolizumab móide Bevacizumab chun ailse ae a chóireáil

13 Iúil 2021: Tá cógas nua do dhaoine le cineál ailse ae ar a dtugtar carcinoma heipiteoceallach ar fáil ar cosúil go bhfuil sé níos fearr ná teiripe caighdeánach (HCC). Cheadaigh an Riarachán Bia agus Drugaí (FDA) atezoliz.

CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, carcinoma heipiteoceallach, Sorafenib, USFDA

Tá Cabozantinib ceadaithe ag FDA le haghaidh carcinoma heipiteoceallach

  On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..

Cóireáil ailse ae i 2023

Burden of liver cancer Liver cancer is a common malignant tumor accounting for more than half of the global liver cancer. The onset of hepatocellular carcinoma (HCC) is hidden, and early symptoms are not obvious. Most people ..

Imdhíteiripe is déanaí i gcóireáil ailse ae

Ailse ae Is í ailse ae an cúigiú cúis báis is coitianta ar domhan ar domhan faoi láthair. Is é an druga cóireála sistéamach den chéad líne reatha ná sorafenib den chuid is mó, ach de ghnáth ní shíneann sé ach maireachtáil iomlán 3 mhí.

Imdhíteiripe NK Cell i gcásanna ardteicneolaíochta ailse ae

Cásanna imdhíonteiripe cealla NK le haghaidh ailse ae chun cinn Tá loghadh iomlán déanta ag othar ailse chun cinn 92 bliain d'aois Seacht mbliana ó shin, diagnóisíodh Ms M, a bhí ina 80í, le carcanóma hepatocellular (de bharr ailse sa lch.